‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

Dimitrios C. Mastellos; Anna M. Blom; E. Sander Connolly; Mohamed R. Daha; Brian V. Geisbrecht; Berhane Ghebrehiwet; Piet Gros; George Hajishengallis; V. Michael Holers; Markus Huber-Lang; Taroh Kinoshita; Tom E. Mollnes; Robert A. Montgomery; B. Paul Morgan; Bo Nilsson; Ruben Pio; Daniel Ricklin; Antonio M. Risitano; Ronald P. Taylor; Alberto Mantovani; John P.A. Ioannidis; John D. Lambris

doi:10.1038/s41590-019-0503-1

‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

Dimitrios C. Mastellos
, Anna M. Blom
, E. Sander Connolly
, Mohamed R. Daha
, Brian V. Geisbrecht
, Berhane Ghebrehiwet
, Piet Gros
, George Hajishengallis
, V. Michael Holers
, Markus Huber-Lang
, Taroh Kinoshita
, Tom E. Mollnes
, Robert A. Montgomery
, B. Paul Morgan
, Bo Nilsson
, Ruben Pio
, Daniel Ricklin
, Antonio M. Risitano
, Ronald P. Taylor
, Alberto Mantovani

John P.A. Ioannidis, John D. Lambris

Allergy and Immunology

Stony Brook University

Demokritos National Centre for Scientific Research
Lund University
Columbia University
Leiden University
Kansas State University
Utrecht University
University of Pennsylvania
University of Colorado Anschutz Medical Campus
Ulm University
The University of Osaka
University of Oslo
Northern Norway Regional Health Authority
Norwegian University of Science and Technology
New York University
Cardiff University
Uppsala University
University of Navarra
University of Basel
University of Naples Federico II
University of Virginia
IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
Stanford University

Research output: Contribution to journal › Comment/debate

12 Scopus citations

Original language	English
Pages (from-to)	1409-1413
Number of pages	5
Journal	Nature Immunology
Volume	20
Issue number	11
DOIs	https://doi.org/10.1038/s41590-019-0503-1
State	Published - Nov 1 2019

Access to Document

10.1038/s41590-019-0503-1

Cite this

Mastellos, D. C., Blom, A. M., Connolly, E. S., Daha, M. R., Geisbrecht, B. V., Ghebrehiwet, B., Gros, P., Hajishengallis, G., Holers, V. M., Huber-Lang, M., Kinoshita, T., Mollnes, T. E., Montgomery, R. A., Morgan, B. P., Nilsson, B., Pio, R., Ricklin, D., Risitano, A. M., Taylor, R. P., ... Lambris, J. D. (2019). ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology, 20(11), 1409-1413. https://doi.org/10.1038/s41590-019-0503-1

@article{52fadf231e8e4c9bb4b87f460628f12b,

title = "{\textquoteleft}Stealth{\textquoteright} corporate innovation: an emerging threat for therapeutic drug development",

author = "Mastellos, \{Dimitrios C.\} and Blom, \{Anna M.\} and Connolly, \{E. Sander\} and Daha, \{Mohamed R.\} and Geisbrecht, \{Brian V.\} and Berhane Ghebrehiwet and Piet Gros and George Hajishengallis and Holers, \{V. Michael\} and Markus Huber-Lang and Taroh Kinoshita and Mollnes, \{Tom E.\} and Montgomery, \{Robert A.\} and Morgan, \{B. Paul\} and Bo Nilsson and Ruben Pio and Daniel Ricklin and Risitano, \{Antonio M.\} and Taylor, \{Ronald P.\} and Alberto Mantovani and Ioannidis, \{John P.A.\} and Lambris, \{John D.\}",

year = "2019",

month = nov,

day = "1",

doi = "10.1038/s41590-019-0503-1",

language = "English",

volume = "20",

pages = "1409--1413",

journal = "Nature Immunology",

issn = "1529-2908",

publisher = "Nature Research",

number = "11",

}

Mastellos, DC, Blom, AM, Connolly, ES, Daha, MR, Geisbrecht, BV, Ghebrehiwet, B, Gros, P, Hajishengallis, G, Holers, VM, Huber-Lang, M, Kinoshita, T, Mollnes, TE, Montgomery, RA, Morgan, BP, Nilsson, B, Pio, R, Ricklin, D, Risitano, AM, Taylor, RP, Mantovani, A, Ioannidis, JPA & Lambris, JD 2019, '‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development', Nature Immunology, vol. 20, no. 11, pp. 1409-1413. https://doi.org/10.1038/s41590-019-0503-1

TY - JOUR

T1 - ‘Stealth’ corporate innovation

T2 - an emerging threat for therapeutic drug development

AU - Mastellos, Dimitrios C.

AU - Blom, Anna M.

AU - Connolly, E. Sander

AU - Daha, Mohamed R.

AU - Geisbrecht, Brian V.

AU - Ghebrehiwet, Berhane

AU - Gros, Piet

AU - Hajishengallis, George

AU - Holers, V. Michael

AU - Huber-Lang, Markus

AU - Kinoshita, Taroh

AU - Mollnes, Tom E.

AU - Montgomery, Robert A.

AU - Morgan, B. Paul

AU - Nilsson, Bo

AU - Pio, Ruben

AU - Ricklin, Daniel

AU - Risitano, Antonio M.

AU - Taylor, Ronald P.

AU - Mantovani, Alberto

AU - Ioannidis, John P.A.

AU - Lambris, John D.

PY - 2019/11/1

Y1 - 2019/11/1

UR - https://www.scopus.com/pages/publications/85074108014

U2 - 10.1038/s41590-019-0503-1

DO - 10.1038/s41590-019-0503-1

M3 - Comment/debate

C2 - 31562490

SN - 1529-2908

VL - 20

SP - 1409

EP - 1413

JO - Nature Immunology

JF - Nature Immunology

IS - 11

ER -

‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

Access to Document

Other files and links

Fingerprint

Cite this